Theriva Biologics says Nature Medicine publishes Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer

Bitget2026/10/01 02:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Theriva Biologics reported Nature Medicine publication of detailed Phase 2b VIRAGE results for VCN-01 in metastatic pancreatic cancer.
Results were previously presented; the publication follows peer review and positions the dataset for broader clinical and investor scrutiny.
VCN-01 with standard gemcitabine and nab-paclitaxel showed better patient outcomes than chemotherapy alone, supporting continued development.
Survival patterns and response timing were consistent with an immune-mediated effect, strengthening rationale for combination strategies.
A Phase 2a VIRAGE2 study is underway to test more frequent repeat dosing; initial safety and pharmacodynamic data are expected in Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609302234OMX_____CNEWS_ES_GNW9837602_es) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Theriva Biologics says Nature Medicine publishes Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer

You may also like

Crypto prices